Buy / Hold Stocks

[gfp927z]

>>> Zoetis -- Animal health specialist Zoetis has hit the ground running, more than quintupling its payouts since initiating its dividend in 2013. Zoetis is the largest business of its kind, creating vaccines, medicines, and diagnostics for pets and livestock, and generating $8.2 billion in sales and $2.2 billion in net income over the last year.


https://www.fool.com/investing/2023/09/07/4-top-dividend-payers-of-the-sp-500/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article


The company is incredibly well-balanced with its products ranging from dermatology and osteoarthritis pain treatments to parasitic medicines and medicated feed additives. Zoetis generates 64% of its revenue from pets and 36% from livestock. Meanwhile, U.S. sales account for 54% of total revenue, while international markets comprise 46%.

Best yet for investors, Zoetis has 15 drugs that each earn over $100 million in annual revenue, highlighting the depth of its product offering and the strength of its research and development (R&D) capabilities. With 11% of its 13,800 employees working in R&D, this innovation is well-funded and should maintain a robust pipeline for decades ahead.

With Zoetis' rising ROIC of 19% and small payout ratio of 29%, look for it to provide above-average dividend growth. But with the shares trading at 40 times earnings and offering a 0.8% dividend, it may be best to buy on drops or though dollar cost averaging.

<<<



---